Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

This study has been terminated.
(Drug provider withdrew support)
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01003678
First received: October 27, 2009
Last updated: June 1, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)